Dear Editor,
We would like to comment on the article, entitled “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study [
[1]
]." Although the majority of IBD patients exhibited seropositivity following COVID-19 vaccinations, Macaluso et al. found that the size of the humoral response was much lower than in HCs [- Macaluso F.S.
- Principi M.
- Facciotti F.
- Contaldo A.
- Todeschini A.
- Saibeni S.
- et al.
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
Dig Liver Dis. 2022; (In press. https://doi.org/10.1016/j.dld.2022.08.027.)
[1]
]. These results appear to be mostly unrelated to the use of immune-modifying therapies, in contrast to those of other research [- Macaluso F.S.
- Principi M.
- Facciotti F.
- Contaldo A.
- Todeschini A.
- Saibeni S.
- et al.
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
Dig Liver Dis. 2022; (In press. https://doi.org/10.1016/j.dld.2022.08.027.)
[1]
]. Numerous variables could have a substantial impact on the COVID-19 vaccination's efficacy. Different doses and administration techniques are available. Compared to a typical, healthy vaccine recipient, patients who use prescription medicines or have underlying medical conditions may be more susceptible to immunizations. We can all agree that it is a good idea to administer the COVID-19 vaccine. The relatively common precursor COVID-19 without symptoms might possibly play a role [- Macaluso F.S.
- Principi M.
- Facciotti F.
- Contaldo A.
- Todeschini A.
- Saibeni S.
- et al.
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
Dig Liver Dis. 2022; (In press. https://doi.org/10.1016/j.dld.2022.08.027.)
[2]
].Testing is frequently skipped to rule out a prior, asymptomatic COVID-19 infection. Regular blood testing can reveal more about a person's underlying immunological issues. It is possible to more precisely forecast how the COVID-19 vaccination will perform by routinely tracking people's underlying immunological disorders. This is an important consideration when determining the efficacy or safety of a vaccination. Despite the fact that there is frequently little information available regarding pre-vaccination immunological or health status, and the possibility of confounding with non-symptomatic SARS-Co-V2 infection cannot be effectively ruled out, numerous studies have demonstrated the efficacy, safety, or clinical significance of the COVID-19 vaccine. Finally, a recent study found a link between vaccine recipients' baseline genetic variation and their immunological response to vaccination [
[3]
]. If additional research is planned, the implications of the genetic polymorphism should be evaluated.Declaration of Competing Interest
None.
References
- Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.Dig Liver Dis. 2022; (In press. https://doi.org/10.1016/j.dld.2022.08.027.)
- Letter to the Editor: coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period.J Prev Med Public Health. 2020; 53: 70
- GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine.Front Genet. 2022; 13932043
Article info
Publication history
Published online: October 18, 2022
Accepted:
September 28,
2022
Received:
September 21,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD studyDigestive and Liver DiseaseVol. 55Issue 2
- Reply to Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease”Digestive and Liver DiseaseVol. 55Issue 1
- PreviewFirst, we would like to thank Dr. Sookaromdee and colleagues for the interest in our study [1]. Currently, there is general consensus on the strong utility of the COVID-19 vaccines, particularly for “frail” subjects and this includes patients with chronic conditions such as inflammatory bowel disease (IBD) [2]. Our study's focus moved from the necessity to understand which factors could have a substantial impact on the efficacy and safety of COVID-19 vaccines. In this regard, the influence of the variables at baseline was investigated using binary logistic regression multivariate analyses for seropositivity rates, and using linear regression multivariate analyses for anti-SARS-CoV-2 IgG levels.
- Full-Text
- Preview
